Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity, Diabetes Mellitus
Interventions
Behavioral and Drug, Behavioral
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
North Chicago, Illinois
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Obesity
Interventions
Phentermine 37.5 Mg, Dietary program, Exercise program
Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Obesity
Interventions
VI-0521, Placebo matched phentermine/topiramate
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Ridgefield, Connecticut • Durham, North Carolina + 2 more
Conditions
Obesity
Interventions
Phentermine Pill, Orforglipron
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Colitis, Ulcerative, Obesity
Interventions
Phentermine-Topiramate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Chronic Weight Management
Interventions
lorcaserin + phentermine placebo, lorcaserin + phentermine-HCl + phentermine placebo, lorcaserin + phentermine-HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 10 more
Conditions
Obesity
Interventions
VI-0521, topiramate, phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Conditions
Obesity
Interventions
Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Childhood Obesity
Interventions
Phentermine, Placebo
Drug
Lead sponsor
Russell McCulloh, MD
Network
Eligibility
12 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Baton Rouge, Louisiana • Kansas City, Missouri • Lebanon, New Hampshire + 3 more
Conditions
Obesity
Interventions
Phentermine-Topiramate Extended Release, Placebo, Online support system
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity
Interventions
Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Phentermine and B12 on Weight Loss Among Obese Patients

NCT01719185
Conditions
Obesity, Hypertension
Interventions
Phentermine and B12, Phentermine
Drug
Lead sponsor
Dr. Michael Lang
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Active, not recruiting Early Phase 1 Interventional Results available

Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

NCT04881799
Conditions
Pediatric Obesity
Interventions
Phentermine/Topiramate (Qsymia), Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 20 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Weight Loss, Obesity, Childhood, Obesity
Interventions
Lomaira 8Mg Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
12 Months to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Loma Linda, California
Conditions
Obesity, Overweight, Metabolic Diseases
Interventions
Low Calorie Diet (LCD), Phentermine
Behavioral · Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Topiramate-Phentermine Combinations for Cocaine Dependence

NCT02239913
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo, Phentermine, Topiramate
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 4 Interventional Results available

Lifestyle Modification and Liraglutide

NCT02911818
Conditions
Obesity
Interventions
CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling
Behavioral · Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more